Vialwirebiotech, curated
November 21, 2026, 5:54 AM
November 13, 2026
- 4:31 AM · Pharmaceutical Technology4:31 AMBMS sets unified research and development structure for 2027 — Pharmaceutical Technology
- 4:30 AM · STAT News
- 4:25 AM · Pharmaceutical Technology4:25 AMTakeda begins US distribution of narcolepsy type 1 drug Orzeyful — Pharmaceutical Technology
- 4:00 AM · Labiotech (EU)4:00 AMInside Arbor’s CNS pipeline and next-generation gene editing — Labiotech (EU)
November 12, 2026
- 8:22 PM · BioPharma Dive8:22 PMWindward prices $175M IPO to advance China-licensed lung drugs — BioPharma Dive
- 8:01 PM · SCMP — Tech8:01 PMEli Lilly beats Novo Nordisk to China approval for first oral GLP-1 weight-loss drug — SCMP — Tech
- 3:15 PM · Nikkei Asia3:15 PMPfizer offshoot Zoetis lines up 'potential blockbuster' pet meds for Japan — Nikkei Asia
- 11:31 AM · STAT News11:31 AMSTAT+: Blackstone backs Pfizer’s bet on monthly obesity treatment — STAT News
- 11:00 AM · BioWorld11:00 AMVectory raises $83.5M, expands ALS trial of anti-TDP-43 gene therapy — BioWorld
- 10:58 AM · Wired — Science10:58 AMSynchron Pauses Trials of Its Brain Implant Due to Performance Issues — Wired — Science
- 9:38 AM · BioPharma Dive9:38 AMThe FDA has over 1k open jobs — and the staffing shortage is hitting pharma — BioPharma Dive
- 8:00 AM · BioWorld8:00 AMChina’s NMPA clears Simcere’s SIM-0725 for clinic — BioWorld
- 8:00 AM · BioWorld8:00 AMA28 Therapeutics’ AT-101 reduces HCC tumor growth — BioWorld
- 8:00 AM · BioWorld8:00 AMTarget designation in Fauna Bio and Lilly’s obesity collaboration — BioWorld
- 8:00 AM · BioWorld8:00 AMCommit Biologics nominates COM-002 as development candidate — BioWorld
- 8:00 AM · BioWorld8:00 AMSAB-05 shows disease control in autoimmune disease — BioWorld
- 8:00 AM · BioWorld8:00 AMJNJ-9401 enhances T-cell responses via CD28 costimulation — BioWorld
- 8:00 AM · BioWorld8:00 AMLexeo’s LX-2021 rescues cardiac stability in cardiomyopathy — BioWorld
- 8:00 AM · BioWorld8:00 AMRoche identifies new amylin receptor agonists — BioWorld
- 6:30 AM · STAT News6:30 AMSTAT+: What to know about Biogen’s big lupus study readout — STAT News
- 6:30 AM · STAT News
- 5:14 AM · Pharmaceutical Technology5:14 AMFDA and EMA waive paediatric studies for Shanton’s gout candidate — Pharmaceutical Technology
- 5:00 AM · SCMP — Tech5:00 AMFormer ByteDance AI scientist touts drug-discovery model that tops world leaders — SCMP — Tech
- 4:31 AM · Pharmaceutical Technology4:31 AMLitmys and PharmaACE partner on pharma commercial forecasting — Pharmaceutical Technology
November 11, 2026
- 2:44 PM · STAT News2:44 PMSTAT+: Most-favored nations policy makes drugmakers rethink launches abroad — STAT News
- 11:00 AM · BioWorld11:00 AMDaz impressive: Amgen phase III nets dual upside in Sjogren’s — BioWorld
- 11:00 AM · BioWorld11:00 AMOyster raises $60M A2 for protein degraders that reach the brain — BioWorld
- 11:00 AM · BioWorld11:00 AMPinpoint test targets cancer triage in major UK trial — BioWorld
- 11:00 AM · BioWorld11:00 AMModerna CEO: Laying ground for cancer vaccine to sell more than Keytruda — BioWorld
- 8:00 AM · BioWorld8:00 AMIaso’s IASO-208 obtains clinical trial clearance in China — BioWorld
- 8:00 AM · BioWorld8:00 AMAstellas’ ASP-388B shows promise for B7H3+ tumors — BioWorld
- 8:00 AM · BioWorld8:00 AMLiver-targeted FASN inhibition for MASH — BioWorld
- 8:00 AM · BioWorld8:00 AMMetagenomi’s MGX-001 gains IND clearance for hemophilia A — BioWorld
- 6:00 AM · Drug Discovery World6:00 AMFcRn inhibitor demonstrates sustained IgG reduction in Phase I trial — Drug Discovery World